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Abstract 19 
 20 
Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 21 
KRVSLWDOL]DWLRQVDQGGHDWKVDQQXDOO\PRVWO\RFFXUULQJLQDGXOWV\HDUVROGVHQLRUV$-participant, 22 
randomized controlled clinical trial (FIM12; Clinicaltrials.gov NCT01427309) showed that high-dose inactivated 23 
influenza vaccine (IIV-HD) is superior to standard-dose vaccine (SD) in preventing laboratory-confirmed influenza 24 
illness in seniors. In this study, we performed a cost-utility analysis (CUA) of IIV-HD versus SD in FIM12 25 
participants from a Canadian perspective.  Healthcare resource utilization data collected in FIM12 included: 26 
medications, non-routine/urgent care and emergency room visits, and hospitalizations. Unit costs were applied using 27 
standard Canadian cost sources to estimate the mean direct medical and societal costs associated with each vaccine 28 
(2014 CAD). Clinical illness data from the trial were mapped to quality-of-life data from the literature to estimate 29 
differences in effectiveness between vaccines. Time horizon was one influenza season, however, quality-adjusted 30 
life-years (QALYs) lost due to death during the study were captured over a lifetime. A probabilistic sensitivity 31 
analysis (PSA) was also performed.  Average per-participant medical costs were $47 lower and societal costs $60 32 
lower in the IIV-HD arm. Hospitalizations contributed 91% of the total cost and were less frequent in the IIV-HD 33 
arm. IIV-HD provided a gain in QALYs and, due to cost savings, dominated SD in the CUA. The PSA indicated 34 
that IIV-HD is 89% likely to be cost saving.  In Canada, IIV-HD is expected to be a less costly and more effective 35 
alternative to SD, driven by a reduction in hospitalizations. 36 
 37 
Keywords: influenza, high-dose inactivated influenza vaccine, Fluzone, cost-utility, cost-effectiveness 38 
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Introduction 40 
 41 
Seasonal influenza infects approximately 10-20% of the Canadian population each year. While most people recover 42 
within 7 to 10 days, severe illness can occur which causes an estimated 12,200 hospitalizations and 3,500 deaths 43 
annually.1 These deaths primarily occur in adults aged 65 and older (herein referred to as seniors) who are more 44 
susceptible to downstream complications associated with influenza infection.2, 3  Because seniors are at greater risk, 45 
the National Advisory Committee on Immunization (NACI) encourages all Canadian seniors to receive a 46 
vaccination each autumn.1 47 
 48 
In the Canadian provinces, publicly-funded immunization programs provide free vaccine to all eligible members of 49 
the public. Trivalent inactivated influenza vaccine (IIV3) is the current vaccine funded for seniors in most provinces. 50 
A new high dose IIV3 vaccine (Fluzone High-Dose; IIV-HD) was approved September 2015 by Health Canada 51 
based on evidence from a randomized controlled trial (RCT) demonstrating improvements in efficacy over standard 52 
dose IIV3 vaccine (SD) in seniors.4 The FIM12 study (Clinicaltrials.gov NCT01427309) showed IIV-HD to be 53 
superior to SD in preventing laboratory-confirmed influenza caused by any type or sub-type associated with 54 
clinically relevant illness in approximately 32,000 seniors (relative efficacy, 24.2%, 95% CI 9.7±36.5%).5  55 
Importantly, the study captured the seasonal variation typical of influenza activity as it was conducted over two 56 
sequential influenza seasons.6-9  The 2011/12 season featured low levels of influenza circulation and a close match 57 
between the vaccine and circulating strains,6 while the 2012/13 season was more severe with a poor match between 58 
vaccine and circulating strains.7-9 59 
 60 
Although the acquisition cost of the IIV-HD is higher than that of SD, healthcare funding decision-makers need to 61 
consider all relevant costs of alternative interventions in relation to the resulting health outcomes. Formal techniques 62 
of economic evaluation, such as cost-effectiveness analysis (CEA), can be used to provide valuable information to 63 
decision makers regarding efficient allocation of finite healthcare resources. Using detailed data on healthcare 64 
utilization (HCU) and clinical outcomes collected from participants in the FIM12 trial, we have previously 65 
demonstrated IIV-HD to be a less costly and more effective alternative to SD in a United States (US)-focused cost-66 
utility analysis (CUA) conducted from both a Medicare and societal perspective. Mean per-participant medical costs 67 
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(in 2014 USD) were lower in the IIV-HD group ($1376.72 USD) than in the SD group ($1492.64; difference ±68 
$115.92). Further, the IIV-HD vaccine provided a gain in quality-adjusted life-years (QALYs; mean 8.1502 69 
QALYs/participant) compared with the SD vaccine (8.1499 QALYs/participant) and, due to cost savings driven 70 
primarily by fewer hospitalizations among subjects vaccinated with IIV-HD, dominated SD in the CUA.10 The 71 
objective of the current analysis was to determine if vaccination with the newly approved IIV-HD versus SD would 72 
lead to similar economic benefits in Canada when Canadian unit costs and survival data were considered in place of 73 
those used in our US analysis. 74 
 75 
Results 76 
 77 
Based on our analysis of HCU, per-participant visits to the emergency room (ER) and non-routine/urgent care visits 78 
were slightly higher in the IIV-HD group than in the SD group, and slightly lower for prescription and non-79 
prescription medication use (Table 1, full analysis set). The mean per-participant number of hospitalizations was 80 
0.0937 (1,498 hospitalizations in 15,990 participants) in the IIV-HD group and 0.1017 (1,629 hospitalizations in 81 
15,993 participants) in the SD group, with averages of 0.4869 days and 0.5626 days for hospital length of stay 82 
(LOS) per-participant, respectively.  83 
 84 
Table 1. Outcomes per participant 85 
 86 
Ninety-one percent of the total healthcare payer costs and 76% of the total societal costs were due to hospital 87 
admissions. The total costs per participant were $60 higher in the SD group compared to the IIV-HD group. Further, 88 
utilizing IIV-HD instead of SD, representing an additional expenditure of $25.97/participant, yielded a 181% 89 
financial return ($47.15/participant) to the healthcare system mainly through reductions in hospital admissions 90 
(Table 2).  91 
 92 
Table 2. Costs by resource item (in 2014 Canadian dollars/participant) 93 
 94 
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The QALY analysis predicted that IIV-HD recipients would experience 7.5533 QALYs over the remainder of their 95 
lifetime, whereas SD recipients would have 7.5530 QALYs, a difference of 0.0003 QALYs in favor of IIV-HD 96 
(Table 2 and Table 4). For a cohort the size of the IIV-HD recipients in the clinical trial (N=15,990), this equates to 97 
an additional 4.8 QALYs for the cohort.  Since total costs were lower in the IIV-HD group and the health outcomes 98 
were more favorable for IIV-HD, the cost-effectiveness analysis found that IIV-HD dominated (i.e., IIV-HD 99 
provided more health at lower costs) SD vaccine from both the public payer and societal perspectives. A threshold 100 
analysis determined that vaccination with IIV-HD continued to be cost-saving to the public payer up to a IIV-HD 101 
price of approximately $79 per injection.  IIV-HD remained dominant in the two sub-group analyses in study 102 
participants with one or more comorbid conditions and in participants 75 years (societal perspective only). In the 103 
public payer perspective analysis involving the subgroup of participants 75 years, a small incremental cost-104 
effectiveness ratio (ICER) of $82/QALY gained was obtained due to slightly higher costs (<$1) and QALYs 105 
(0.0049) among participants in the IIV HD group compared to the SD group (Table 3).  106 
 107 
Table 3. Cost utility analysis 108 
 109 
In the cardiorespiratory condition analysis IIV-HD recipients gained more QALYs over their lifetime than SD 110 
recipients and their healthcare system and societal costs were also less (Tables 2-4). The total costs per participant 111 
were $29 lower in the IIV-HD group than they were in the SD group. The expenditure required to administer IIV-112 
HD instead of SD ($25.97/participant) yielded an 80% financial return ($20.65/participant) to the healthcare system 113 
(Table 3), and vaccination with IIV-SD remained cost-saving up to a cost per injection of approximately $53. 114 
Further, IIV-HD remained dominant in the cost-effectiveness analysis including all sub-group analysis (Table 4). 115 
 116 
ICERs computed in the PSA revealed that 89% of the points in the full-analysis set and 83% of the points in the 117 
cardiorespiratory analysis set clustered in the lower quadrants of the plot (Figure 1). Further, in the cardiorespiratory 118 
set 80% of the samples clustered in the lower right quadrant. These results illustrate that IIV-HD is less costly than 119 
SD with high certainty. The cardiorespiratory analysis also illustrates that reduction in cardio-respiratory 120 
complications provide much of the health benefits offered by IIV-HD. 121 
 122 
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Figure 1. Scatterplots representing the statistical uncertainty through a 1,000 bootstrapped samples 123 
 124 
Discussion 125 
 126 
In this Canadian economic evaluation based on a RCT of approximately 32,000 seniors, we found that IIV-HD was 127 
a cost-saving alternative to SD, the current standard of care for ambulatory seniors in most provinces, and this 128 
conclusion was robust in the face of statistical uncertainty. From the societal perspective, savings were estimated to 129 
be $60 per IIV-HD participant when considering the full analysis set and $29 per IIV-HD participant when 130 
considering the cardiorespiratory condition analysis set. Savings to the healthcare payer were slightly less, at 131 
approximately $47 and $21 per IIV-HD participant, respectively. Since the price of IIV-HD has not been established 132 
in Canada yet, we used the US price assuming a 1:1 exchange rate (based on exchange rates current at the time the 133 
study was conducted; $31.81 per injection); however, the actual Canadian launch price will depend on a number of 134 
factors such as, for example, global supply and demand constraints and changes in exchange rates. Therefore, we 135 
conducted threshold analyses on IIV-HD price which determined that the price could increase to just under $79 (full 136 
analysis set) and $53 (cardiorespiratory condition analysis set) per injection and still be cost saving to healthcare 137 
payers. As noted, the majority of the savings generated by IIV-HD were driven by reductions in cardiorespiratory 138 
hospitalizations plausibly related to influenza.  139 
 140 
Our previous analysis based on the same RCT, but conducted from the Medicare and societal perspectives in the US, 141 
found similar results, though the magnitude of the cost savings was higher in the US (e.g., $128 and $80 USD 142 
(2014) per IIV-HD participant based on the full and cardiorespiratory condition analysis sets, respectively). This 143 
difference was driven by the fact that hospital per diems were, on average, approximately 51% (or ~$1,400/day 144 
without adjustment for exchange rate) lower in Canada than in the US.10 The only other IIV-HD cost-effectiveness 145 
study identified in the literature was a mathematical modeling study (discussed in depth in our previous publication 146 
10) which predicted that the IIV-HD would be a cost-effective alternative to SD (incremental cost-effectiveness ratio 147 
$5,399 USD/QALY gained).11 148 
 149 
 7 
 
A key feature of this study is that it uses a randomized head-to-head design (FIM12), to define causality between the 150 
vaccines and healthcare resource consumption. The FIM12 RCT was sufficiently large to observe the cost-saving 151 
signal generated by IIV-HD from background noise (heterogeneous healthcare expenditures amongst seniors). 152 
Further, the healthcare cost data we used are directly applicable to Canadian public payers as they were obtained 153 
from Ontario sources, which is the largest province by population in Canada.  154 
 155 
The study also had a number of limitations beyond those previously discussed.10 As noted, FIM12 was a 156 
multinational study, however, only 5% of participants were enrolled in Canada while the remaining 95% of 157 
participants were from the US. For our analysis, all HCU data were pooled across all patients even though it is 158 
conceivable that HCU may potentially have been affected by differences in the structure of healthcare delivery 159 
systems, practice patterns, and the availability and access to healthcare services between the two countries. 160 
Statistical testing was conducted prior to data pooling, which did not detect heterogeneity among HCU between 161 
countries. Therefore, it was justified to pool the trial data for all analyses. 162 
 163 
Another limitation is that the collection of per diems for assignment to each hospitalization required some 164 
simplifying techniques to manage the data collection burden. As has been explained, hospitalizations were 165 
categorized into a manageable number of groups using the Medical Dictionary for Regulatory Activities (MedDRA) 166 
coding system, which were first mapped to an International Classification of Diseases, Ninth Edition, Clinical 167 
Revision (ICD-9-CM) code(s) and then, specifically for the Canadian analysis, to an ICD Tenth Edition (ICD-10) 168 
code(s) for per diem cost collection and assignment from the Ontario Case Costing Initiative (OCCI) database. 169 
Although this approach was used consistently across all hospitalizations regardless of vaccine group, it is possible 170 
that some specificity was lost during the grouping and two-step mapping process. To limit the potential for error 171 
and/or inaccurate assignment of codes, the same analyst with medical training completed both steps of the mapping 172 
exercise, and all mappings were reviewed by a physician at Sanofi Pasteur. 173 
 174 
Finally, it is worth noting that our study was a comparison of vaccination with IIV-HD against SD, which is the 175 
current standard of care for seniors in most Canadian provinces. However, other vaccines such as standard dose 176 
quadrivalent inactivated influenza vaccine and adjuvanted trivalent inactivated influenza vaccine are used for seniors 177 
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in some provinces and long-term care facilities. Since our analysis was based on data collected in a head-to-head 178 
trial comparing only IIV-HD versus SD, we did not consider the cost-effectiveness of IIV-HD compared to other 179 
vaccines. 180 
 181 
In conclusion, after accounting for the price difference between IIV-HD and SD, vaccination with IIV-HD resulted 182 
in cost savings to the public payer and to society in Canada. This was driven by a reduction in the number of 183 
hospitalizations. As the clinical benefits are higher for IIV-HD and associated total costs are lower, it dominated SD 184 
in the CUA. 185 
 186 
Patients and Methods 187 
 188 
Analytic approach 189 
 190 
The methods developed for this analysis of the economic impact of IIV-HD versus SD in Canada as measured in the 191 
FIM12 trial5 have been described in detail in a previous publication of a CUA conducted for the US.10 Here we 192 
provide a general overview of these analytic methods along with a detailed description of the adaptations made to 193 
the analysis specifically for the Canadian setting.  194 
 195 
Briefly, FIM12 was a head-to-head RCT of IIV-HD versus SD (randomized 1:1) that enrolled approximately 32,000 196 
seniors over two influenza seasons (2011/2012 and 2012/2013). A surveillance program captured HCU data for all 197 
study participants, including use of prescription and non-prescription medications (limited to 198 
antipyretics/analgesics/non-steroidal anti-inflammatory drugs, antivirals, and antibiotics), emergency room ER 199 
visits, non-routine/urgent care visits, and hospitalizations, if they occurred within 30 days after any study respiratory 200 
illness (the frequency and types of respiratory illnesses have been described in the original trial publication5). In 201 
addition, hospitalizations resulting from serious events (serious events were defined as events: leading to death or 202 
hospitalization (or its prolongation); considered as life-threatening or medically important; or resulting in disability) 203 
were captured for all participants and for the duration of the study, regardless of their occurrence in relation to a 204 
study respiratory illness.5  205 
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 206 
Our primary analysis estimated Canadian public healthcare system expenditures based directly on the HCU data 207 
collected in each arm of the FIM12 study. In exploratory analyses, we also examined differences in costs not 208 
covered by the public payer, including out-of-pocket costs for non-prescription medications and work force 209 
productivity losses. Further, we estimated the incremental cost-utility of IIV-HD versus SD. To perform the CUA, 210 
we modeled the expected impacts of the medical events captured in FIM12 on quality of life (QoL) during the 211 
clinical trial period and throughout the life expectancy of the study cohort. Modeled health outcomes that extended 212 
beyond the study duration were discounted at five percent annually; costs were not discounted since they were based 213 
only on HCU reported during the trial period and did not extend beyond one year.12 All costs were reported in 2014 214 
Canadian dollars. 215 
 216 
Costing analysis 217 
 218 
Although FIM12 was a multinational study, only 5% of participants were enrolled in Canada while the remaining 219 
95% of participants were from the US. Prior to pooling HCU data across all participants, tests of significance were 220 
performed to detect potential differences in utilization patterns between the US versus Canada. Specifically, we 221 
assessed the impact of vaccine strategy on the total intensity of HCU across countries using the total medical cost, in 222 
a single currency (2014 USD), for each subject as a proxy measure for overall HCU intensity. A regression analysis, 223 
using a gamma regression model, was conducted with HCU intensity (cost) as the dependent measure and the 224 
independent measures were vaccine group, country, and an interaction term between vaccine group and country. It is 225 
the interaction term, or whether there is a similar effect of study treatment on the incremental cost difference across 226 
countries, that determines whether it is appropriate to pool all participants in a straightforward way.13 Because there 227 
was not a significant interaction between vaccine group and country with outcome considered to be the total medical 228 
cost (p=0.96; i.e., heterogeneity among HCU was not detected between countries), it was justified to pool the trial 229 
data for all analyses. 230 
 231 
The pooled healthcare resources for all subjects in the trial were valued using unit prices relevant to Canada from 232 
standard sources. In cases where costs were not available in 2014 dollars, they were inflated using the healthcare 233 
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component of the consumer price index (CPI).14 Total costs were calculated from the quantity of resources 234 
consumed (for example, number of days hospitalized) and the unit cost per resource. The analysis from the public 235 
payer perspective considered the following costs: vaccine, prescription medication, medical visits, and 236 
hospitalizations. The analysis from the societal perspective additionally included the costs of non-prescription 237 
medication and lost work force productivity.  238 
 239 
Since IIV-HD was not marketed in Canada at the time of the study, it was assumed the list price would be the same 240 
as in the US (since the USD and Canadian dollar were approximately at par when the study was conducted 241 
(2013/2014)) obtained from the Centers for Medicare & Medicaid Services (CMS) Seasonal Influenza Vaccines 242 
Pricing List.15  The cost of SD was provided by Sanofi Pasteur.16 The cost per unit for each prescription medication 243 
was obtained from the Ontario Drug Benefit Formulary (used as a proxy for Canada).17 The cost per prescription 244 
included an 8% upcharge and $8.83 dispensing fee per length of treatment.18  The unit cost for non-prescription 245 
medications (societal perspective only) was obtained from a large Canadian pharmacy chain.19  246 
 247 
The unit costs for respiratory illness-related ER and non-routine/urgent care visits were obtained from Canadian 248 
Institute for Health Information (CIHI) reports.20, 21 The costs of hospitalizations were calculated by multiplying the 249 
hospital LOS by the unit cost per day (per diem). To estimate the per diem cost, diagnosis codes related to 250 
hospitalizations were grouped into preferred terms under the MedDRA coding system and mapped to the ICD-9-CM 251 
codes (for the purpose of assigning costs in the original US analysis).  The ICD-9-CM codes were then mapped to 252 
ICD-10 codes for the purpose of extracting and assigning per diem costs from the OCCI¶V on-line database.22 253 
 254 
Productivity costs were imputed using methods described by Molinari et al. in which the number of medical visits 255 
per participant represented the number of days of productivity lost (at a ratio of one visit: one day of lost 256 
productivity).23 The number of days of lost productivity was valued at the average daily wage for Canadian 257 
employees in 2014.24 All unit costs used in the analysis are provided in Table 4. 258 
 259 
Table 4. Unit Costs of Resource Items (2014 Canadian dollars) 260 
 261 
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Cost-effectiveness 262 
 263 
An ICER was calculated for IIV-HD versus SD. The ICER was defined as (CostIIV-HD - CostSD)/(OutcomesIIV-HD - 264 
OutcomesSD). The costs and outcomes were the total costs and outcomes from each arm of the FIM12 trial. We also 265 
calculated ICERs for the following two subgroups: participants with one or more co-morbid condition (N=21,502) 266 
and participants 75 years of age (N=10,839). 267 
 268 
The outcome of the CUA was the QALY. To estimate the number of QALYs in each vaccine arm we first estimated 269 
the total number of life-years (LYs) per arm. We used age- and gender-specific Canadian life expectancy data from 270 
Statistics Canada to estimate the LYs for study participants.25 When weighted according to the FIM12 gender 271 
distribution (43% male, 57% female), the mean life expectancy for subjects in FIM12, prior to adjustments for 272 
discounting and deaths experienced during the trial was 9.9 years. After applying an annual discount rate of 5%, 273 
mean life expectancy for subjects in FIM12 was 7.6 years. For each subject who died during the study, their 274 
remaining length of life was calculated based only on the amount of time for which they survived following 275 
vaccination (date of death - date of vaccination + 1). 276 
 277 
Since QoL data were not collected in the FIM12 trial, we adjusted the LYs to estimate QALYs using QoL data 278 
VSHFLILFWRWKHSDUWLFLSDQW¶VDJHJHQGHUDQGWKHPHGLFDOHYHQWVWKH\H[SHULHQFHGGXULQJWKHVWXG\$GGLWLRQDOGHWDLOV 279 
regarding the methodology including the utility and disutility values applied in our analysis have been reported in 280 
our previously published CUA.10  281 
 282 
Subgroup and uncertainty analysis 283 
As FIM12 was not powered for the purpose of this economic evaluation, it was possible that the economic benefit of 284 
IIV-HD would be difficult to detect due to the multiple non-influenza related events collected in the FIM12 study. 285 
To overcome this and to increase the specificity of our analysis we planned a cardiorespiratory condition analysis 286 
that accounted for a subset of clinical outcomes selected by study clinicians before unblinding the study based on the 287 
plausibility of their relation to influenza. Outcomes groupings included pneumonia events, asthma/chronic 288 
obstructive pulmonary disease/bronchial events, influenza events (serious laboratory-confirmed influenza diagnosed 289 
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outside study procedures by a SDUWLFLSDQW¶VKHDOWKFDUHSURYLGHURWKHUUHVSLUDWRU\HYHQWVFRURQDU\DUWHU\HYHQWV290 
congestive heart failure events, and cerebrovascular events. A more granular listing of the conditions included in this 291 
subgroup and the methods used to identify these events has previously been published by DiazGranados et al., 292 
2015.26   293 
 294 
To explore the impact of statistical uncertainty on the results we conducted a bootstrapping analysis of the trial data 295 
with replacement as described in our previous work.10 Results are presented as a scatterplot on a cost-effectiveness 296 
plane.27  297 
 298 
 299 
  300 
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